论文部分内容阅读
目的:探讨毛细支气管炎应用氨溴特罗口服液联合孟鲁司特治疗的临床疗效。方法:80例毛细支气管炎患儿随机分为两组:对照组40例应用常规综合治疗,观察组40例在对照组的基础上加用氨溴特罗联合孟鲁司特治疗,比较两组的临床疗效。结果:观察组的临床治疗总有效率显著高于对照组(97.50%vs85.00%),组间比较差异具有统计学意义(P<0.05);观察组的喘憋、咳嗽及肺部哮鸣音等症状体征消退时间均较对照组显著缩短(P<0.05);观察组不良反应率与对照组比较(2.50%vs0.00%)差异不具有统计学意义(P>0.05)。结论:氨溴特罗联合孟鲁司特辅助治疗毛细支气管炎能够促进临床症状和体征的消退,提高临床疗效,且副作用较少,值得临床推广。
OBJECTIVE: To investigate the clinical efficacy of amiloride oral combined with montelukast in the treatment of bronchiolitis. Methods: Eighty children with bronchiolitis were randomly divided into two groups: the control group of 40 cases were treated by conventional combination therapy, the observation group of 40 cases were treated with ambroxol and montelukast on the basis of the control group, and the two groups were compared The clinical efficacy. Results: The total effective rate of clinical observation in the observation group was significantly higher than that in the control group (97.50% vs 85.00%), with significant difference between the two groups (P <0.05); wheezing, cough and wheezing in the observation group (P0.05). There was no significant difference in adverse reaction rate between the observation group and the control group (2.50% vs0.00%) (P> 0.05). Conclusion: The combination of ambroxol and montelukast in the treatment of bronchiolitis can promote the regression of clinical symptoms and signs and improve the clinical curative effect with less side effects, which is worthy of clinical promotion.